COX-2 selective nonsteroidal anti-inflammatory drugs: current status
1Rheumatology Clinic, Postgraduate Department of Medicine, Government Medical College, Jammu.
Summary
Cyclooxygenase-2 (COX-2) inhibitors, while popular, carry significant risks including cardiovascular events and congenital defects. Careful patient selection is crucial due to their potential for serious adverse effects.
Area of Science:
- Pharmacology
- Drug Safety
- Cardiovascular Medicine
Background:
- Cyclooxygenase-2 (COX-2) specific inhibitors represent a significant and growing market segment.
- Concerns regarding the potentially lethal side effects of COX-2 inhibitors have prompted regulatory action and research focus.
Purpose of the Study:
- To review the adverse effects associated with COX-2 specific inhibitors.
- To highlight the risks of cardiovascular thrombotic events, hypertension, and other serious complications.
- To discuss the implications for neonatal development and pregnancy.
Main Methods:
- Literature review of studies on COX-2 inhibitor side effects.
- Analysis of FDA actions and reported adverse events.
- Synthesis of information on COX-2 enzyme function and inhibition consequences.
Main Results:
- FDA has banned nimesulide (hepatotoxic) and rofecoxib (cardiovascular complications).
- COX-2 inhibition can disrupt vascular prostacyclin/thromboxane balance, increasing thrombotic risk.
- Adverse effects include hypertension, skin reactions, heart failure exacerbation, and potential congenital defects.
Conclusions:
- COX-2 inhibitors pose risks including cardiovascular events, organ damage, and developmental issues.
- Use in pregnant or potentially pregnant women should be avoided due to implantation interference.
- Patient selection requires careful consideration of efficacy, toxicity, and individual health factors.
Related Concept Videos
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...